Table 2 Association of genotypes with respect to the three candidate SNPs with tumour responses in patients treated with cetuximab and bevacizumab regimensa

From: Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer

  

Overall response rates b

DCRs b

Gene SNPs

Genotypes

Responders/subgroups (%)

OR

95% CI

P- value c

Responders/subgroups (%)

OR

95% CI

P -value c

Cetuximab regimens

LIFR rs3729740

GG

30/68 (44.1)

1

  

54/68 (79.4)

1

0.194–0.961

 
 

GA+AA

13/56 (23.2)

0.383

0.175–0.838

0.022

35/56 (62.5)

0.432

 

0.046

ISX rs361863

CC

33/92 (35.9)

1

  

68/92 (73.9)

1

  
 

CT+TT

10/32 (31.3)

0.813

0.344–1.921

0.673

21/32 (65.6)

0.674

0.284–1.601

0.372

Bevacizumab regimens

ANXA11 rs1049550

CC+CT

10/48 (20.8)

1

  

27/48 (56.3)

1

  
 

TT

22/52 (42.3)

2.787

1.147–6.77

0.031

40/52 (76.9)

2.593

1.096–6.133

0.034

  1. Abbreviations: CI=confidence interval; CR=complete response; DCR=disease-control rate; 5-FU=5-fluorouracil; OR=odds ratio; PD=progressive disease; PR=partial response; SD=stable disease; SNP=single-nucleotide polymorphism.
  2. Bold font, P<0.05.
  3. aEither irinotecan or oxaliplatin was combined to cetuximab with 5-FU/leucovorin (FL) or capecitabine, namely, FOLFIRI and XELIRI or FOLFOX and XELOX.
  4. bAssessment using RECIST criteria (Therasse et al, 2000). Overall response (OR=CR+PR) and disease-control (DCR=CR+PR+SD) rates.
  5. cAll genotypes were compared by dominant model, except for ANXA11 rs1049550 (recessive model), using Fisher’s exact test.
Back to article page